The Safety and Efficacy of JAK Inhibitors: Have We Found the Right Pathway?

IF 2.4 4区 医学 Q2 RHEUMATOLOGY
Lei Wang, Yung-Heng Lee, Xin-lei Yang, Po-Cheng Shih, Jin-fang Gao, Li-yun Zhang
{"title":"The Safety and Efficacy of JAK Inhibitors: Have We Found the Right Pathway?","authors":"Lei Wang,&nbsp;Yung-Heng Lee,&nbsp;Xin-lei Yang,&nbsp;Po-Cheng Shih,&nbsp;Jin-fang Gao,&nbsp;Li-yun Zhang","doi":"10.1111/1756-185X.70130","DOIUrl":null,"url":null,"abstract":"<p>Elderly patients with autoimmune diseases require long-term medication and physiotherapy, which also involves lifestyle modification. Ongoing follow-up and treatment lead to frequent consumption of healthcare resources, including outpatient visits, hospitalization, examinations, and medicines, putting financial pressure on patients and families. At the same time, the loss of patients' labor force has socioeconomic implications. Among drug therapies, Janus kinase (JAK) inhibitors are an important class of drugs that have shown significant efficacy in the treatment of autoimmune and inflammatory diseases. However, the issue of selectivity of these drugs has been a challenge in clinical application. Nonselective JAK inhibitors may lead to adverse events, including infections, hematologic alterations, cardiovascular and thrombotic risks, and possible malignancy risks, limiting their use. Nevertheless, the significance of selectivity in achieving effective treatment responses and minimizing adverse events remains uncertain.</p>","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 5","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1756-185X.70130","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Rheumatic Diseases","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/1756-185X.70130","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Elderly patients with autoimmune diseases require long-term medication and physiotherapy, which also involves lifestyle modification. Ongoing follow-up and treatment lead to frequent consumption of healthcare resources, including outpatient visits, hospitalization, examinations, and medicines, putting financial pressure on patients and families. At the same time, the loss of patients' labor force has socioeconomic implications. Among drug therapies, Janus kinase (JAK) inhibitors are an important class of drugs that have shown significant efficacy in the treatment of autoimmune and inflammatory diseases. However, the issue of selectivity of these drugs has been a challenge in clinical application. Nonselective JAK inhibitors may lead to adverse events, including infections, hematologic alterations, cardiovascular and thrombotic risks, and possible malignancy risks, limiting their use. Nevertheless, the significance of selectivity in achieving effective treatment responses and minimizing adverse events remains uncertain.

JAK抑制剂的安全性和有效性:我们是否找到了正确的途径?
患有自身免疫性疾病的老年患者需要长期的药物和物理治疗,这也包括改变生活方式。持续的随访和治疗导致医疗资源的频繁消耗,包括门诊就诊、住院、检查和药物,给患者和家庭带来了经济压力。与此同时,患者劳动力的流失具有社会经济影响。在药物治疗中,Janus kinase (JAK)抑制剂是一类重要的药物,在自身免疫性疾病和炎症性疾病的治疗中显示出显著的疗效。然而,这些药物的选择性问题在临床应用中一直是一个挑战。非选择性JAK抑制剂可能导致不良事件,包括感染、血液学改变、心血管和血栓形成风险,以及可能的恶性肿瘤风险,限制了它们的使用。然而,选择性在实现有效治疗反应和减少不良事件方面的重要性仍然不确定。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.70
自引率
4.00%
发文量
362
审稿时长
1 months
期刊介绍: The International Journal of Rheumatic Diseases (formerly APLAR Journal of Rheumatology) is the official journal of the Asia Pacific League of Associations for Rheumatology. The Journal accepts original articles on clinical or experimental research pertinent to the rheumatic diseases, work on connective tissue diseases and other immune and allergic disorders. The acceptance criteria for all papers are the quality and originality of the research and its significance to our readership. Except where otherwise stated, manuscripts are peer reviewed by two anonymous reviewers and the Editor.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信